Based on these premises, the possibility of enalkiren to modulate the renin-angiotensin system without altering patient susceptibility to the virus, together with inhibition of the SARS-CoV-2 Mpro, may exhibit beneficial effects for COVID-19 treatment. This evidence concerns the gene REN and COVID-19.